Denali Therapeutics Inc. (DNLI)
DNLI moved a median of +0.07% 30 minutes after news, and +0.46% by the close. How DNLI actually reacts to news — the realized, point-in-time move the market made, measured across 316 labeled events over the last three years with zero look-ahead.
DNLI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.03% | 47% | 316 |
| 30-min | +0.07% | 51% | 316 |
| 60-min | +0.21% | 54% | 316 |
| to close | +0.46% | 57% | 312 |
| Middle 50% of DNLI reactions | -1.25% to +1.16% |
|---|---|
| Median reaction (30-min) | +0.07% |
| Measured reactions | 316 |
Half of all Denali Therapeutics Inc. news events land between -1.25% and +1.16% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How DNLI reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 26 | +0.39% | 69% | +2.81% |
| Rating reiterations | 83 | -0.18% | 47% | +0.39% |
| Price-target raises | 14 | -0.81% | 14% | -1.94% |
| Price-target cuts | 21 | 0.00% | 48% | -0.36% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how DNLI ranks against every other measured name →
That’s how DNLI usually reacts — get an email when it moves on news →Email me when DNLI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DNLI's baseline. Nothing else.
Recent DNLI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights | Press release | GlobeNewswire | -0.63% | -2.51% | |
| Form 10-Q Denali Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.63% | -2.51% | |
| Form 8-K Denali Therapeutics Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -0.63% | -2.51% | |
| Form 8-K Denali Therapeutics Inc. For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | +0.54% | |
| Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 | Press release | GlobeNewswire | -0.42% | +0.54% | |
| Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier | Press release | GlobeNewswire | -1.77% | -5.10% | |
| Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Press release | GlobeNewswire | +0.14% | -3.80% | |
| Form 8-K Denali Therapeutics Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | -3.80% | |
| Form 8-K Denali Therapeutics Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | +2.23% | |
| Form 8-K Denali Therapeutics Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -0.82% | -1.32% | |
| Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease | Press release | GlobeNewswire | -0.82% | -1.32% | |
| Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights | Press release | GlobeNewswire | +2.29% | +0.93% | |
| Form 10-Q Denali Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.29% | +0.93% | |
| Form 8-K Denali Therapeutics Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +2.29% | +0.93% | |
| Form ARS Denali Therapeutics Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.84% | -0.15% | |
| Form DEF 14A Denali Therapeutics Inc. For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +0.84% | -0.15% | |
| Form DEFA14A Denali Therapeutics Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.84% | -0.15% | |
| Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) | Press release | GlobeNewswire | -0.78% | -5.92% | |
| Form 8-K Denali Therapeutics Inc. For: Apr 03 | SEC filing · Form 8-K | SEC EDGAR | -0.78% | -5.92% | |
| Form 8-K Denali Therapeutics Inc. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -0.05% | +1.59% | |
| The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step | Press release | Canada Newswire | +0.00% | +0.61% | |
| Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) | Press release | GlobeNewswire | +0.62% | +3.17% | |
| Form 8-K Denali Therapeutics Inc. For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | +1.49% | |
| Advanced Cell-based Therapy Booming the Success for Healthcare Sector | Press release | PR Newswire | -0.12% | +0.91% | |
| Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -2.59% | +1.44% | |
| Form 10-K Denali Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.59% | +1.44% | |
| Form 8-K Denali Therapeutics Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -2.59% | +1.44% | |
| Form S-8 Denali Therapeutics Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.59% | +1.44% | |
| Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development | Press release | GlobeNewswire | +0.03% | +6.08% | |
| Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™ | Press release | GlobeNewswire | +0.20% | -0.25% | |
| Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ | Press release | GlobeNewswire | +0.33% | +6.61% | |
| Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™ | Press release | GlobeNewswire | +3.93% | +2.89% | |
| Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome | Press release | GlobeNewswire | -0.37% | +6.70% | |
| Form 8-K Denali Therapeutics Inc. For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | +6.70% | |
| The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) | Press release | GlobeNewswire | -0.42% | -0.61% | |
| Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +3.29% | -4.41% | |
| Form 8-K Denali Therapeutics Inc. For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | +1.32% | +0.00% | |
| Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +3.29% | -4.41% | |
| Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement | Press release | GlobeNewswire | -0.08% | +7.14% | |
| Form 8-K Denali Therapeutics Inc. For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | -0.08% | +7.14% | |
| Denali Therapeutics Announces Board and Executive Leadership Updates | Press release | GlobeNewswire | +1.19% | +5.26% | |
| Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | +1.19% | +5.26% | |
| Form 10-Q Denali Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.19% | +5.26% | |
| Form 8-K Denali Therapeutics Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +1.19% | +5.26% | |
| Form 8-K Denali Therapeutics Inc. For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -0.90% | +5.04% | |
| Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) | Press release | GlobeNewswire | -0.90% | +5.04% | |
| Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -1.64% | — | |
| Form 10-Q Denali Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.64% | — | |
| Form 8-K Denali Therapeutics Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -1.64% | — | |
| Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) | Press release | GlobeNewswire | -2.21% | -1.72% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DNLI section they belong to.
Where else DNLI is measured.
DNLI earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Senseonics Holdings, Inc. (SENS) | 318 | -0.44% | 42% |
| Allogene Therapeutics, Inc. (ALLO) | 316 | +0.18% | 51% |
| Myomo Inc. (MYO) | 315 | +0.35% | 54% |
| ICU Medical, Inc. (ICUI) | 313 | +0.02% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Denali Therapeutics Inc.'s median reaction calculated?
Every labeled DNLI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 316 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of DNLI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DNLI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.